Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M, Jehn C, Mai EK, Bertsch U, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Raab MS, Luntz SP, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann HW, Weisel K, Duerig J, Goldschmidt H. Salwender H, et al. Among authors: jehn c. Leukemia. 2021 Oct;35(10):3007-3011. doi: 10.1038/s41375-021-01298-y. Epub 2021 May 24. Leukemia. 2021. PMID: 34031532 Clinical Trial. No abstract available.
Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
Elmaagacli AH, Salwender H, Jehn C, Dahmash F, Singh A, Wilson O, Pannenbeckers M, Niggemann C, Vierbuchen M. Elmaagacli AH, et al. Among authors: jehn c. Leuk Lymphoma. 2019 Dec;60(13):3335-3338. doi: 10.1080/10428194.2019.1623887. Epub 2019 Jun 4. Leuk Lymphoma. 2019. PMID: 31164030 No abstract available.
Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.
Elmaagacli AH, Jehn C, Shikova Y, Huber M, Salwender H, Dahmash F, Singh A, Niggemann C, Vierbuchen M. Elmaagacli AH, et al. Among authors: jehn c. Leuk Lymphoma. 2020 Feb;61(2):485-487. doi: 10.1080/10428194.2019.1668939. Epub 2019 Sep 30. Leuk Lymphoma. 2020. PMID: 31566043 No abstract available.
Solitary neuroendocrine carcinoma of the heart: a case report.
Wißt T, Jehn CF, Vierbuchen M, Starekova J. Wißt T, et al. Among authors: jehn cf. Eur Heart J Case Rep. 2018 Sep 12;2(3):yty096. doi: 10.1093/ehjcr/yty096. eCollection 2018 Sep. Eur Heart J Case Rep. 2018. PMID: 31020173 Free PMC article.
38 results